ESTRO meets Asia 2024 - Abstract Book

S176

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

advanced HNC in our local population. We employed immunotherapy only in concomitant setting and not extended as adjuvant as in most published trials so far. Hereby, we present our first interim analysis and highlight the comparison with the recently published trials.

(Clinicaltrials.gov registration NCT03532737 - Kuwait Ministry of Health registration 759/2018)

Material/Methods:

All locally non-nasopharyngeal inoperable/unresectable HNC patients presented to Kuwait Cancer Control Center (KCCC) were offered participation in our trial. They received pembrolizumab 200 mg started 3 weeks before radical CRT, 2-3 cycles pembrolizumab 200 mg every 3 weeks concomitant with platinum during radiation course, and continued 2-3 more cycles of pembrolizumab after finishing radiation for total 6 cycles. VMAT radiation technique was used in all patients with targets and risk organs delineation as per international guidelines. Toxicity profile was recorded according to CTCAE criteria version 5 and response assessed by MRI and PET/CT according to the published protocol.

Results:

Forty patients were eligible for the protocol, of which (due to COVID-19 outbreak and other reasons) 15 patients denied the protocol. From January 2020 till December 2023, we recruited 23 patients with stage III-IVA oral, oropharyngeal or laryngeal cancers and. A couple of p16+ T3N1 patients were included (based on AJCC 7 th ed staging) and will be excluded from the survival analysis later on, but retained in safety phase. Patient characteristics and safety/efficacy data summarized in Table 1 and 2. Compared to the published trails so far, our patients' population is younger, with minimal alcohol intake and same p16 positive oropharyngeal proportion. We included oral cavity more than any of other compared trials, hence more oral mucositis and nutritional toxicity happened. Neverthlesss, advanced oral cavity cases with T4 N1-3 disease achieved and maintained CR so far. Four deaths documented in the early post treatment period; 1 of unrelated condition (COVID-19); 2 suspected treatment related multi-organ failure following neutropenic fever and septicemia, and 1 died of rapid distant disease progression.